shelf(0)

No. 001 · Repair · Recovery Peptide

BPC-157

BPC 157Body Protection Compound-157BepecinPL 14736

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S0
Compare Cite
no sequence C62H98N16O22
O O O O O O O O H O O O O O H O O O O H O O H O O O N N N N H N H N N H N H N 2 H N H N 2 H N H N H N H N H N H

2D structure from PubChem CID 9941957 (Bpc-157), matched by exact name. Hydrogens on carbon are implied.

BPC-157 (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Quick answers

What is BPC-157?
A pentadecapeptide derived from human gastric juice that accelerates healing of muscles, tendons, and ligaments.
How strong is the evidence for BPC-157?
Tier C (animal data) on the peptidemeta evidence scale. Evidence is predominantly from rodent studies; human data are limited to a small retrospective pilot report, and a registered phase 1 trial posted no results.
Is BPC-157 FDA-approved?
No. BPC-157 is not approved by the FDA for any use. FDA has flagged BPC-157 as a bulk substance with potential safety risks for compounding.
Is BPC-157 banned in sport?
Yes. BPC-157 is prohibited in sport by the World Anti-Doping Agency under S0 (non-approved substances).
How does BPC-157 work?
BPC-157 activates the FAK-paxillin pathway and upregulates VEGFR2 expression, promoting angiogenesis and accelerating tendon-to-bone healing. It modulates the nitric oxide (NO) system and has cytoprotective effects on the gastrointestinal mucosa through interaction with the dopamine and serotonin systems.
What is known about the safety of BPC-157?
Generally well-tolerated in animal studies with a wide therapeutic window. No completed human clinical trials to date.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

Evidence is predominantly from rodent studies; human data are limited to a small retrospective pilot report, and a registered phase 1 trial posted no results.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved FDA has flagged BPC-157 as a bulk substance with potential safety risks for compounding.
WADA
Prohibited · S0 Non-approved substances
04

Overview

A pentadecapeptide derived from human gastric juice that accelerates healing of muscles, tendons, and ligaments. Widely studied for its systemic protective effects on the gut and musculoskeletal system.

Research status Extensive preclinical data; numerous animal studies demonstrating systemic healing properties

05

Mechanism

BPC-157 activates the FAK-paxillin pathway and upregulates VEGFR2 expression, promoting angiogenesis and accelerating tendon-to-bone healing. It modulates the nitric oxide (NO) system and has cytoprotective effects on the gastrointestinal mucosa through interaction with the dopamine and serotonin systems.

06

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Accelerated tendon and ligament repair
  • Enhanced gut lining regeneration
  • Reduced inflammation at injury sites
  • Improved angiogenesis and blood flow
07

Safety & unknowns

Generally well-tolerated in animal studies with a wide therapeutic window. No completed human clinical trials to date. Most commonly reported side effects include mild injection site irritation and occasional nausea. Not FDA-approved for any indication. Consult a healthcare provider before use.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [0]

No studies cited for this entry yet.

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). BPC-157. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/bpc-157/

$ cite --format=bibtex 
@misc{peptidemeta-bpc-157,
  title = {BPC-157},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/bpc-157/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open